Skip to main content
Fig. 3 | Clinical Epigenetics

Fig. 3

From: Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival

Fig. 3

Methylation profile of 200 probes at diagnosis predict overall survival in AZA treated patients. Heatmap showing the hierarchical clusterization of the 200 probes obtained with combined rank analysis that are differentially methylated between longer and shorter survivals in bone marrow samples at diagnosis. Selected genes associated with differentially methylated CpGs are indicated

Back to article page
\